We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

216 hedge funds and large institutions have $3.86B invested in Amicus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $4.95M

17% more capital invested

Capital invested by funds: $3.3B → $3.86B (+$557M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 73

2.67% more ownership

Funds ownership: 105.31%107.98% (+2.7%)

4% less funds holding

Funds holding: 226216 (-10)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

Holders
216
Holders Change
-10
Holders Change %
-4.42%
% of All Funds
3.39%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
25
Increased
82
Reduced
73
Closed
32
Calls
$11.5M
Puts
$4.95M
Net Calls
+$6.55M
Net Calls Change
+$8.49M
Name Holding Trade Value Shares
Change
Change in
Stake
ECM
51
ExodusPoint Capital Management
New York
$7.84M +$5.55M +468,018 +300%
Victory Capital Management
52
Victory Capital Management
Texas
$7.52M -$15.6M -1,311,824 -69%
Neuberger Berman Group
53
Neuberger Berman Group
New York
$6.81M +$2.58M +217,430 +67%
MB
54
MPM BioImpact
Massachusetts
$6.48M +$1.52M +127,847 +33%
Swiss National Bank
55
Swiss National Bank
Switzerland
$5.8M +$80.7K +6,800 +1%
CM
56
CM Management
Florida
$5.65M
Ameriprise
57
Ameriprise
Minnesota
$5.44M -$302K -25,462 -6%
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
$5.21M -$149K -12,588 -3%
Barclays
59
Barclays
United Kingdom
$5.09M -$615K -51,810 -11%
UBS Group
60
UBS Group
Switzerland
$5.03M +$1.55M +130,321 +48%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
61
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$5.01M -$16.9M -1,420,577 -78%
IHAM
62
Integral Health Asset Management
New York
$4.86M +$973K +82,000 +27%
Susquehanna International Group
63
Susquehanna International Group
Pennsylvania
$4.58M +$574K +48,340 +15%
Citigroup
64
Citigroup
New York
$4.58M -$2.74M -231,279 -39%
CS
65
Credit Suisse
Switzerland
$4.5M +$798K +67,238 +23%
GLA
66
Great Lakes Advisors
Illinois
$4.49M -$2.57M -216,220 -38%
AllianceBernstein
67
AllianceBernstein
Tennessee
$4.24M +$254K +21,420 +7%
Bank of Montreal
68
Bank of Montreal
Ontario, Canada
$3.8M -$122K -10,319 -3%
FA
69
Faithward Advisors
Pennsylvania
$3.74M -$99.5K -8,389 -3%
TCA
70
Transcend Capital Advisors
New Jersey
$3.59M +$827K +69,686 +32%
SAM
71
Silvercrest Asset Management
New York
$3.52M +$492K +41,488 +17%
California State Teachers Retirement System (CalSTRS)
72
California State Teachers Retirement System (CalSTRS)
California
$3.52M -$93.2K -7,853 -3%
HIM
73
Hillsdale Investment Management
Ontario, Canada
$3.4M -$1.55M -130,320 -33%
EP
74
Edgestream Partners
New Jersey
$3.33M +$3.15M +265,335 New
Allianz Asset Management
75
Allianz Asset Management
Germany
$3.31M +$71.2K +6,002 +2%

FOLD Hedge Fund Activity: Q2 2023 in Review

216 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2023, worth a combined $3.86B — up 17% from $3.3B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of FOLD and 25 opened new positions — a net loss of 7 holders — while 73 trimmed existing stakes and 82 added.

The largest buyer was Deutsche Bank, adding an estimated $61.1M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 216 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2023, down from 226 in Q1 2023.
  • Funds reported $3.86B of Amicus Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
  • 25 funds opened new Amicus Therapeutics positions in Q2 2023 and 32 closed out, a net change of -7 holders.
  • The largest Amicus Therapeutics buyer in Q2 2023 was Deutsche Bank, an estimated $61.1M added.
  • The largest Amicus Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q2 2023.